Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, Status and Forecast 2023-2027

Report ID: 952836 | Published Date: Mar 2026 | No. of Page: 97 | Base Year: 2025 | Rating: 3.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

Impact of U.S Tarrifs Analyzed 2025 

1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Glassia
        1.2.3 Aralast NP
        1.2.4 Prolastin C
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospitals
        1.3.3 Specialty Clinics
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Perspective (2016-2027)
    2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Trends by Regions
        2.2.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Share by Regions (2016-2021)
        2.2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Regions (2022-2027)
    2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Dynamic
        2.3.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends
        2.3.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers
        2.3.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Challenges
        2.3.4 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Revenue
        3.1.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Revenue (2016-2021)
        3.1.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Players (2016-2021)
    3.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue
    3.4 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio
        3.4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2020
    3.5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players Head office and Area Served
    3.6 Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Solution and Service
    3.7 Date of Enter into Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Breakdown Data by Type
    4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size by Type (2016-2021)
    4.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Type (2022-2027)

5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Breakdown Data by Application
    5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size by Application (2016-2021)
    5.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2016-2027)
    6.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
        6.2.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021)
        6.2.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027)
        6.2.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2027)
    6.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
        6.3.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021)
        6.3.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027)
        6.3.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2027)
    6.4 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
        6.4.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021)
        6.4.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2016-2027)
    7.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
        7.2.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021)
        7.2.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027)
        7.2.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2027)
    7.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
        7.3.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021)
        7.3.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027)
        7.3.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2027)
    7.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
        7.4.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021)
        7.4.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2016-2027)
    8.2 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
        8.2.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2027)
    8.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
        8.3.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2027)
    8.4 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region
        8.4.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2016-2027)
    9.2 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
        9.2.1 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021)
        9.2.2 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027)
        9.2.3 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2027)
    9.3 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
        9.3.1 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021)
        9.3.2 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027)
        9.3.3 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2027)
    9.4 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
        9.4.1 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021)
        9.4.2 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2016-2027)
    10.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
        10.2.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2027)
    10.3 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
        10.3.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2027)
    10.4 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
        10.4.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Grifols
        11.1.1 Grifols Company Details
        11.1.2 Grifols Business Overview
        11.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
        11.1.4 Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
        11.1.5 Grifols Recent Development
    11.2 CSL
        11.2.1 CSL Company Details
        11.2.2 CSL Business Overview
        11.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
        11.2.4 CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
        11.2.5 CSL Recent Development
    11.3 Baxter
        11.3.1 Baxter Company Details
        11.3.2 Baxter Business Overview
        11.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
        11.3.4 Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
        11.3.5 Baxter Recent Development
    11.4 Kamada
        11.4.1 Kamada Company Details
        11.4.2 Kamada Business Overview
        11.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
        11.4.4 Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
        11.4.5 Kamada Recent Development
    11.5 Takeda
        11.5.1 Takeda Company Details
        11.5.2 Takeda Business Overview
        11.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
        11.5.4 Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
        11.5.5 Takeda Recent Development
    11.6 Abeona
        11.6.1 Abeona Company Details
        11.6.2 Abeona Business Overview
        11.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
        11.6.4 Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
        11.6.5 Abeona Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Glassia
    Table 3. Key Players of Aralast NP
    Table 4. Key Players of Prolastin C
    Table 5. Key Players of Others
    Table 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2016-2021)
    Table 10. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2022-2027)
    Table 12. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends
    Table 13. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers
    Table 14. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Challenges
    Table 15. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Restraints
    Table 16. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players (2016-2021)
    Table 18. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2020)
    Table 19. Ranking of Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Solution and Service
    Table 23. Date of Enter into Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2016-2021)
    Table 27. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Application (2016-2021)
    Table 31. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021) & (US$ Million) 
    Table 38. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027) & (US$ Million) 
    Table 39. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021) & (US$ Million) 
    Table 44. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027) & (US$ Million) 
    Table 45. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2016-2021) & (US$ Million) 
    Table 50. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2022-2027) & (US$ Million) 
    Table 51. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021) & (US$ Million) 
    Table 56. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027) & (US$ Million) 
    Table 57. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021) & (US$ Million) 
    Table 62. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027) & (US$ Million) 
    Table 63. Grifols Company Details
    Table 64. Grifols Business Overview
    Table 65. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
    Table 66. Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
    Table 67. Grifols Recent Development
    Table 68. CSL Company Details
    Table 69. CSL Business Overview
    Table 70. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
    Table 71. CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
    Table 72. CSL Recent Development
    Table 73. Baxter Company Details
    Table 74. Baxter Business Overview
    Table 75. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
    Table 76. Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
    Table 77. Baxter Recent Development
    Table 78. Kamada Company Details
    Table 79. Kamada Business Overview
    Table 80. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
    Table 81. Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
    Table 82. Kamada Recent Development
    Table 83. Takeda Company Details
    Table 84. Takeda Business Overview
    Table 85. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
    Table 86. Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
    Table 87. Takeda Recent Development
    Table 88. Abeona Company Details
    Table 89. Abeona Business Overview
    Table 90. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
    Table 91. Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
    Table 92. Abeona Recent Development
    Table 93. Research Programs/Design for This Report
    Table 94. Key Data Information from Secondary Sources
    Table 95. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type: 2020 VS 2027
    Figure 2. Glassia Features
    Figure 3. Aralast NP Features
    Figure 4. Prolastin C Features
    Figure 5. Others Features
    Figure 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2020 VS 2027
    Figure 7. Hospitals Case Studies
    Figure 8. Specialty Clinics Case Studies
    Figure 9. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Report Years Considered
    Figure 10. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 12. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions: 2020 VS 2027
    Figure 13. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2022-2027)
    Figure 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players in 2020
    Figure 15. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2020
    Figure 16. The Top 10 and 5 Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2020
    Figure 17. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2016-2021)
    Figure 18. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2022-2027)
    Figure 19. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 20. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2016-2027)
    Figure 21. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2016-2027)
    Figure 22. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2016-2027)
    Figure 23. United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2016-2027)
    Figure 27. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2016-2027)
    Figure 28. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2016-2027)
    Figure 29. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. U.K. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Nordic Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2016-2027)
    Figure 37. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2016-2027)
    Figure 38. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Region (2016-2027)
    Figure 39. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2016-2027)
    Figure 47. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2016-2027)
    Figure 48. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2016-2027)
    Figure 49. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2016-2027)
    Figure 53. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2016-2027)
    Figure 54. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2016-2027)
    Figure 55. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. UAE Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Grifols Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
    Figure 59. CSL Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
    Figure 60. Baxter Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
    Figure 61. Kamada Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
    Figure 62. Takeda Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
    Figure 63. Abeona Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Grifols
CSL
Baxter
Kamada
Takeda
Abeona
Frequently Asked Questions
Alpha-1 Antitrypsin Deficiency Augmentation Therapy report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Alpha-1 Antitrypsin Deficiency Augmentation Therapy report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Alpha-1 Antitrypsin Deficiency Augmentation Therapy report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Vitiligo Treatment

Vitiligo is a common acquired localized or recurrent skin pigment loss disorder. This is caused b ... Read More

Bitcoin Technology

Bitcoin is a consensus network that enables a new payment system and is completely digital money. ... Read More